CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem MeetingsBusiness Wire • 02/03/26
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026The Motley Fool • 02/01/26
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 01/27/26
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 01/12/26
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug ResponseBusiness Wire • 01/07/26
Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to TradeZacks Investment Research • 11/27/25
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung TransplantationBusiness Wire • 11/24/25
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025Business Wire • 11/06/25
CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/05/25
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical OfficerBusiness Wire • 10/27/25
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart FailureBusiness Wire • 10/23/25
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual MeetingBusiness Wire • 10/06/25